Answers are grounded in this paper and cite their sources.
The conventional administration of Mitomycin C (MMC) in intravesical instillations has its limitations. In this study, MMC was loaded onto an in situ forming depot consisting of chitosan (CS), β-glycerophosphate (GP) and Fe3O4 magnetic nanoparticles (Fe3O4-MNPs) to improve its effects. The features and effects of this new drug delivery mode were investigated. The new drug delivery system (Fe3O4-MMC-CS/GP) exhibited superior sol-gel transformation and magnetism. Sustained release of MMC was observed both in vitro and in vivo, and the retention, which lasted for 72 h in the rat bladder, was further examined using frozen sections. The Cell-Counting Kit-8 (CCK-8) and flow cytometry assays revealed better anti-tumor activity of Fe3O4-MMC-CS/GP compared with the free MMC solution. Animal experiments showed that Fe3O4-MMC-CS/GP provided a favorable survival rate and inhibited the growth of bladder tumors. Moreover, this drug delivery system enhanced tumor cell apoptosis compared with the conventional route of MMC administration in rats.
No takes yet. Share an insight, caveat, or question.
Alan C. Sartorelli (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: